Modus Therapeutics: Clinical development pro
Modus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.
She held other leadership positions in Clinical Operations; Project and Portfolio Management at Pfizer and also brings biotech and consulting experience to the CEO role, having worked in positions within U.S. biotech and management consulting. Donnelly received her Ph.D. from Yale University.
Donnelly took up her appointment on 25 April 2017, succeeding Christina Herder.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium